Free Trial

NanoVibronix Q2 2023 Earnings Report

NanoVibronix logo
$0.38 0.00 (-0.31%)
As of 02/21/2025 04:00 PM Eastern

NanoVibronix EPS Results

Actual EPS
-$0.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NanoVibronix Revenue Results

Actual Revenue
$0.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NanoVibronix Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

NanoVibronix Earnings Headlines

NanoVibronix files to sell Series G Convertible Preferred Stock, warrants
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
NanoVibronix completes acquisition of ENvue Medical
See More NanoVibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NanoVibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NanoVibronix and other key companies, straight to your email.

About NanoVibronix

NanoVibronix (NASDAQ:NAOV), through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

View NanoVibronix Profile

More Earnings Resources from MarketBeat